$312 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 66 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | 2SEVENTY BIO INC COM | $0 | – | -48 | -100.0% | -0.04% | – | |
| ANAB | Exit | ANAPTYSBIO INC COM | $0 | – | -203 | -100.0% | -0.10% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC C | $0 | – | -1,567 | -100.0% | -0.13% | – |
| PRTA | Exit | PROTHENA CORP PLC USD0.01 | $0 | – | -407 | -100.0% | -0.16% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS | $0 | – | -128 | -100.0% | -0.17% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS | $0 | – | -401 | -100.0% | -0.17% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -985 | -100.0% | -0.20% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -476 | -100.0% | -0.22% | – |
| BNTX | Exit | BIONTECH SE ADSsponsored ads | $0 | – | -3,847 | -100.0% | -0.27% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS | $0 | – | -441 | -100.0% | -0.33% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS I | $0 | – | -1,470 | -100.0% | -0.34% | – |
| IONS | Exit | IONIS PHARMACEUTICALS INC | $0 | – | -1,703 | -100.0% | -0.48% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLsponsored adr | $0 | – | -122 | -100.0% | -0.52% | – |
| GMAB | Exit | GENMAB -SP ADRsponsored ads | $0 | – | -1,857 | -100.0% | -0.60% | – |
| IMVT | Exit | IMMUNOVANT INC COM | $0 | – | -233 | -100.0% | -0.63% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC C | $0 | – | -1,017 | -100.0% | -0.99% | – |
| GMDA | Exit | GAMIDA CELL | $0 | – | -187 | -100.0% | -1.12% | – |
| CCXI | Exit | CHEMOCENTRYX INC COM STK | $0 | – | -3,000 | -100.0% | -1.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.